
REGENXBIO (RGNX) Stock Forecast & Price Target
REGENXBIO (RGNX) Analyst Ratings
Bulls say
Regenxbio is a strong buy due to its promising pipeline of investigational gene therapy treatments, positive results in recent clinical trials, and expected regulatory approvals in the near future. The company's cash runway is also expected to last into early 2027, providing financial stability. However, risks to price target achievement include potential failures in clinical trials and competition in the market. With an estimated market value of $1.64B, analysts have a price target of $26 per share, indicating a strong upside potential.
Bears say
Regenxbio is a clinical-stage biotechnology company with a 12-month price target of $26 per share and a total estimated market value of $1.64B. However, there are significant risks associated with this valuation, including the possibility of unsuccessful clinical trials, failure to secure regulatory approval, and potential challenges in achieving commercial success. Additionally, potential dilution risk could also impact the price target.
This aggregate rating is based on analysts' research of REGENXBIO and is not a guaranteed prediction by Public.com or investment advice.
REGENXBIO (RGNX) Analyst Forecast & Price Prediction
Start investing in REGENXBIO (RGNX)
Order type
Buy in
Order amount
Est. shares
0 shares